Header

Gastrointestinal Malignancies Clinical Trials

Category:Adult
Status:Active

Displaying trials 1 - 30 of 41 in total

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be ran...

Diagnosis: Gastrointestinal Malignancies, Liver Cancer

Phase: 3

Protocol Number: 15-287

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors

This is a Phase 3, prospective, multi-center, randomized, double-blind, study evaluating the efficacy and safety of LAN plus BSC versus placebo plus BSC for the treatment of well-differentiated, me...

Diagnosis: Gastrointestinal Malignancies

Phase: 3

Protocol Number: 16-032

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca

The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with p...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase: 3

Protocol Number: 16-146

Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer

The purpose of this study is to determine whether nivolumab will improve overall survival, disease-free survival, or both compared with placebo.

Diagnosis: Esophageal Cancer, Gastrointestinal Malignancies

Phase: 3

Protocol Number: 16-197

Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

This randomized phase III trial studies how well gemcitabine hydrochloride and cisplatin with or without radiation therapy work in treating patients with localized liver cancer that cannot be remov...

Diagnosis: Liver Cancer, Gastrointestinal Malignancies

Phase: 3

Protocol Number: 15-710

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to s...

Diagnosis: Colorectal Cancer, Gastrointestinal Malignancies

Phase: 2 / 3

Protocol Number: 12-023

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

This research study is a Phase II clinical trial to test the safety and effectiveness of the investigational drug Ziv-aflibercept in combination with mFOLFOX6 compared to mFOLFOX6 alone. The drugs ...

Diagnosis: Gastrointestinal Malignancies, Esophageal Cancer, Stomach Cancer

Phase: 2

Protocol Number: 12-401

Sorafenib + mFOLFOX for Hepatocellular Carcinoma

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational combination of drugs to learn whether the drug combination works in treating ...

Diagnosis: Gastrointestinal Malignancies, Liver Cancer

Phase: 2

Protocol Number: 12-218

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigat...

Diagnosis: Gastrointestinal Malignancies, Neuroendocrine/Carcinoid

Phase: 2

Protocol Number: 12-456

Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer

The purpose of this research study is to see if cancer will respond better to a combination of irinotecan and cetuximab with or without bevacizumab

Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer

Phase: 2

Protocol Number: 14-574

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.

Diagnosis: Neuroendocrine/Carcinoid, Gastrointestinal Malignancies

Phase: 2

Protocol Number: 16-072

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unre...

Diagnosis: Gastrointestinal Malignancies, Esophageal Cancer

Phase: 2

Protocol Number: 15-545

Pembrolizumab in Refractory Metastatic Anal Cancer

This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab

Diagnosis: Gastrointestinal Malignancies

Phase: 2

Protocol Number: 16-301

Gemcitabine Plus BPM31510 Administered Intravenously in Advanced Pancreatic Cancer Patients

This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of the combination of BPM31510 administered as a 144-hour continuous intravenous (IV) infusio...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase: 2

Protocol Number: 17-066

Safety and Efficacy of FGF401 in Patients With Solid Malignancies

Estimate the maximum tolerated dose and/or recommended phase two dose and efficacy of FGF401 on patients with solid malignancies

Diagnosis: Gastrointestinal Malignancies, Stomach Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer

Phase: 1 / 2

Protocol Number: 14-464

A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer

The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (H...

Diagnosis: Gastrointestinal Malignancies

Phase: 1 / 2

Protocol Number: 15-142

A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

This is a randomized phase II multi-institution prospective open label study in which up to 90 subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who previously ...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase: 1 / 2

Protocol Number: 14-568

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocr...

Diagnosis: Neuroendocrine/Carcinoid, Gastrointestinal Malignancies

Phase: 1 / 2

Protocol Number: 16-450

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal juncti...

Diagnosis: Esophageal Cancer, Gastrointestinal Malignancies

Phase: 1 / 2

Protocol Number: 16-258

A Study of DKN-01 in Combination With Paclitaxel

A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel in participants with refractory/recurrent esophageal or gastro-esophageal junction cancer.

Diagnosis: Gastrointestinal Malignancies

Phase: 1

Protocol Number: 14-004

Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) of MGD007 administered on either weekly or every three...

Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer

Phase: 1

Protocol Number: 14-524

Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.

This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the ...

Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer

Phase: 0

Protocol Number: 14-091

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Undergoing Surgery

This pilot clinical trial studies the best dose of erlotinib hydrochloride and to see how well it works in preventing liver cancer in patients with scarring (cirrhosis) of the liver undergoing surg...

Diagnosis: Gastrointestinal Malignancies

Phase: N/A

Protocol Number: 14-333

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using...

Diagnosis: Colorectal Cancer, Esophageal Cancer, Gastrointestinal Malignancies, Pancreatic Cancer

Phase: N/A

Protocol Number: 13-415

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

The purpose of this research study is to address the challenge of medication management for older patients undergoing treatment for cancer. The sponsor of this protocol is the Massachusetts General...

Diagnosis: Breast: Early Stage Disease, Lung Cancer, Gastrointestinal Malignancies

Phase: N/A

Protocol Number: 16-230

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sora...

Diagnosis: Gastrointestinal Malignancies

Phase:

Protocol Number: 15-108

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.

Diagnosis: Gastrointestinal Malignancies

Phase:

Protocol Number: 14-246

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 15-191

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC. Safety will be measured by looking at the adverse even...

Diagnosis: Liver Cancer, Gastrointestinal Malignancies, Pediatric Oncology

Phase:

Protocol Number: 15-450

Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of ...

Diagnosis: Gastrointestinal Malignancies, Neuroendocrine/Carcinoid

Phase:

Protocol Number: 16-705

1
<< Previous
'